<DOC>
	<DOCNO>NCT01048268</DOCNO>
	<brief_summary>The purpose study determine whether glucose-dependent insulinotropic polypeptide ( GIP ) stabilize function blood glucose</brief_summary>
	<brief_title>Glucose-dependent Insulinotropic Polypeptide - New Role Blood Glucose Stabilizer ?</brief_title>
	<detailed_description>The aim study investigate effect GIP glucagon secretion hyper- , eu- hypoglycemia healthy volunteer , patient type 1 diabetes mellitus patient type 2 diabetes mellitus . From , evaluate GIP 's role blood sugar stabilizer .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Gastric Inhibitory Polypeptide</mesh_term>
	<criteria>Caucasians T1DM ( diagnose accord WHO 's criterion ) without residual beta cell function ( arginine test without increase cpeptide ) treatment long act insulin OR Caucasians noninsulin treat T2DM ( diagnose accord WHO 's criterion ) OR Caucasians without first degree relative diabetes mellitus , normal fast plasma glucose glucose tolerance along negative islet GAD65 autoantibody AND Normal hemoglobin Informed consent Exclusion criterion : Unwillingness participate wish leave present study HbA1c &gt; 9 % Liver disease ( ALAT ASAT &gt; 2 time normal value ) Diabetic nephropathy ( serum creatinin &gt; 130 microM and/or albuminury ) Proliferative diabetic retinopathy ( anamnetic ) Atherosclerotic heart disease heart failure ( NYHA group III IV ) Anemia Treatment medicine pause 12 hour Pregnancy and/or breast feeding Fasting plasma glucose &gt; 15 mM day experiment</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>T1DM</keyword>
	<keyword>T2DM</keyword>
	<keyword>GIP</keyword>
	<keyword>Glucose-dependent insulinotropic polypeptide</keyword>
	<keyword>Incretin</keyword>
</DOC>